Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection

详细信息    查看全文

• 作者：Ole Lagatie (1)
  Tom Van Loy (1)
  Luc Tritsmans (2)
  Lieven J Stuyver (1)
  
  1. Janssen Diagnostics ; Turnhoutseweg 30 ; 2340 ; Beerse ; Belgium
  2. Janssen Research and Development ; Turnhoutseweg 30 ; 2340 ; Beerse ; Belgium
  
• 关键词：JC Polyomavirus ; Biomarker ; Peptide serology ; VP2 ; Progressive Multifocal Leukoencephalopathy
• 刊名：Virology Journal
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：11
• 期：1
• 全文大小：1,890 KB
• 参考文献：1. Frisque, RJ, Bream, GL, Cannella, MT (1984) Human polyomavirus JC virus genome. J Virol 51: pp. 458-469
  2. Padgett, BL, Rogers, CM, Walker, DL (1977) JC virus, a human polyomavirus associated with progressive multifocal leukoencephalopathy: additional biological characteristics and antigenic relationships. Infect Immun 15: pp. 656-662
  3. Berger, JR, Major, EO (1999) Progressive multifocal leukoencephalopathy. Semin Neurol 19: pp. 193-200 CrossRef
  4. Padgett, BL, Walker, DL, ZuRhein, GM, Eckroade, RJ, Dessel, BH (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1: pp. 1257-1260 CrossRef
  5. Dubois, V, Dutronc, H, Lafon, ME, Poinsot, V, Pellegrin, JL, Ragnaud, JM, Ferrer, AM, Fleury, HJ (1997) Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol 35: pp. 2288-2292
  6. Andreoletti, L, Dubois, V, Lescieux, A, Dewilde, A, Bocket, L, Fleury, HJ, Wattre, P (1999) Human polyomavirus JC latency and reactivation status in blood of HIV-1-positive immunocompromised patients with and without progressive multifocal leukoencephalopathy. Aids 13: pp. 1469-1475 30-199908200-00005" target="_blank" title="It opens in new window">CrossRef
  7. Weissert, R (2011) Progressive multifocal leukoencephalopathy. J Neuroimmunol 231: pp. 73-77 CrossRef
  8. Gasparovic, ML, Gee, GV, Atwood, WJ (2006) JC virus minor capsid proteins Vp2 and Vp3 are essential for virus propagation. J Virol 80: pp. 10858-10861 CrossRef
  9. Shishido-Hara, Y, Ichinose, S, Higuchi, K, Hara, Y, Yasui, K (2004) Major and minor capsid proteins of human polyomavirus JC cooperatively accumulate to nuclear domain 10 for assembly into virions. J Virol 78: pp. 9890-9903 CrossRef
  10. Giorda, KM, Raghava, S, Zhang, MW, Hebert, DN (2013) The viroporin activity of the minor structural proteins VP2 and VP3 is required for SV40 propagation. J Biol Chem 288: pp. 2510-2520 CrossRef
  11. Knowles, WA, Pipkin, P, Andrews, N, Vyse, A, Minor, P, Brown, DW, Miller, E (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71: pp. 115-123 CrossRef
  12. Lee, P, Plavina, T, Castro, A, Berman, M, Jaiswal, D, Rivas, S, Schlain, B, Subramanyam, M (2013) A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57: pp. 141-146 CrossRef
  13. Major, EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61: pp. 35-47 CrossRef
  14. Van Loy, T, Thys, K, Tritsmans, L, Stuyver, LJ (2013) Quasispecies analysis of JC virus DNA present in urine of healthy subjects. PLoS One 8: pp. e70950 CrossRef
  15. Padgett, BL, Walker, DL (1973) Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 127: pp. 467-470 CrossRef
  16. Taguchi, F, Kajioka, J, Miyamura, T (1982) Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 26: pp. 1057-1064 CrossRef
  17. Walker, DL, Padgett, BL (1983) The epidemiology of human polyomaviruses. Prog Clin Biol Res 105: pp. 99-106
  18. Randhawa, P, Viscidi, R, Carter, JJ, Galloway, DA, Culp, TD, Huang, C, Ramaswami, B, Christensen, ND (2009) Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol 90: pp. 634-639 CrossRef
  19. Viscidi, RP, Clayman, B (2006) Serological cross reactivity between polyomavirus capsids. Adv Exp Med Biol 577: pp. 73-84 CrossRef
  20. Dominguez-Mozo, MI, Garcia-Montojo, M, De Las, HV, Garcia-Martinez, A, Arias-Leal, AM, Casanova, I, Arroyo, R, Alvarez-Lafuente, R (2013) Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab. J Neuroimmune Pharmacol 8: pp. 1277-1286 CrossRef
  21. Plavina, T, Berman, M, Njenga, M, Crossman, M, Lerner, M, Gorelik, L, Simon, K, Schlain, B, Subramanyam, M (2012) Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 53: pp. 65-71 CrossRef
  22. Warnke, C, Pawlita, M, Dehmel, T, Posevitz-Fejfar, A, Hartung, HP, Wiendl, H, Kieseier, BC, Adams, O (2013) An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Mult Scler 19: pp. 1137-1144 CrossRef
  23. Kean, JM, Rao, S, Wang, M, Garcea, RL (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5: pp. e1000363 CrossRef
  24. Moens, U, Van Ghelue, M, Song, X, Ehlers, B (2013) Serological cross-reactivity between human polyomaviruses. Rev Med Virol 23: pp. 250-264 CrossRef
  Anti- John Cunningham Virus (JCV) antibodies measured by Enzyme Linked Immunosorbent Assay (ELISA); 510(k) Number: K112394.
  25. Zhang, NN, Zhao, LQ, Qian, Y, Zhu, RN, Deng, J, Wang, F, Sun, Y, Liu, LY (2013) Common WU polyomavirus infection in a Beijing population indicated by surveillance for serum IgG antibody against capsid protein VP2. World J Pediatr 9: pp. 48-52 CrossRef
  26. Corallini, A, Mazzoni, E, Taronna, A, Manfrini, M, Carandina, G, Guerra, G, Guaschino, R, Vaniglia, F, Magnani, C, Casali, F, Dolcetti, R, Palmonari, C, Rezza, G, Martini, F, Barbanti-Brodano, G, Tognon, MG (2012) Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Hum Immunol 73: pp. 502-510 CrossRef
  27. Mueller, K, Schachtner, T, Sattler, A, Meier, S, Friedrich, P, Trydzenskaya, H, Hinrichs, C, Trappe, R, Thiel, A, Reinke, P, Babel, N (2011) BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation 91: pp. 100-107 CrossRef
  28. Stuyver, LJ, Verbeke, T, Van Loy, T, Van Gulck, E, Tritsmans, L (2013) An antibody response to human polyomavirus 15-mer peptides is highly abundant in healthy human subjects. Virol J 10: pp. 192 CrossRef
  29. Cunningham, BC, Wells, JA (1993) Comparison of a structural and a functional epitope. J Mol Biol 234: pp. 554-563 CrossRef
  30. Cunningham, BC, Wells, JA (1989) High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244: pp. 1081-1085 CrossRef
  31. Zheng, HY, Sugimoto, C, Hasegawa, M, Kobayashi, N, Kanayama, A, Rodas, A, Mejia, M, Nakamichi, J, Guo, J, Kitamura, T, Yogo, Y (2003) Phylogenetic relationships among JC virus strains in Japanese/Koreans and Native Americans speaking Amerind or Na-Dene. J Mol Evol 56: pp. 18-27 CrossRef
  32. Altschul, SF, Gish, W, Miller, W, Myers, EW, Lipman, DJ (1990) Basic local alignment search tool. J Mol Biol 215: pp. 403-410 CrossRef
  33. Egli, A, Infanti, L, Dumoulin, A, Buser, A, Samaridis, J, Stebler, C, Gosert, R, Hirsch, HH (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199: pp. 837-846 CrossRef
  34. Antonsson, A, Green, AC, Mallitt, KA, O鈥橰ourke, PK, Pawlita, M, Waterboer, T, Neale, RE (2010) Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 91: pp. 1849-1853 CrossRef
  35. Stolt, A, Sasnauskas, K, Koskela, P, Lehtinen, M, Dillner, J (2003) Seroepidemiology of the human polyomaviruses. J Gen Virol 84: pp. 1499-1504 CrossRef
  36. Frohman, EM, Monaco, MC, Remington, G, Ryschkewitsch, C, Jensen, PN, Johnson, K, Perkins, M, Liebner, J, Greenberg, B, Monson, N, Frohman, TC, Douek, D, Major, EO (2014) JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 71: pp. 596-602 CrossRef
  37. Major, EO, Frohman, E, Douek, D (2013) JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 368: pp. 2240-2241 CrossRef
  38. Major, EO, Frohman, E, Douek, D (2013) More on JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med 369: pp. 1280 CrossRef
  39. Berger, JR, Houff, SA, Gurwell, J, Vega, N, Miller, CS, Danaher, RJ (2013) JC virus antibody status underestimates infection rates. Ann Neurol 74: pp. 84-90 CrossRef
  40. Diotti, RA, Mancini, N, Clementi, N, Sautto, G, Moreno, GJ, Criscuolo, E, Cappelletti, F, Man, P, Forest, E, Remy, L, Giannecchini, S, Clementi, M, Burioni, R (2014) Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy. Antivir Res 108: pp. 94-103 CrossRef
  41. Streckert, HJ, Sommerfeld, HJ, Morgenroth, K, Werchau, H (1992) Recognition of SV40-VP2 in the infected cell by antipeptide antibodies. Arch Virol 123: pp. 399-407 CrossRef
  42. Chen, XS, Stehle, T, Harrison, SC (1998) Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. EMBO J 17: pp. 3233-3240 CrossRef
  43. Burkert, O, Kressner, S, Sinn, L, Giese, S, Simon, C, Lilie, H (2014) Biophysical characterization of polyomavirus minor capsid proteins. Biol Chem 395: pp. 871-880 CrossRef
  44. Lagatie, O, Van Loy, T, Tritsmans, L, Stuyver, LJ (2014) Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects. Virol J 11: pp. 41 CrossRef
  45. Alland, C, Moreews, F, Boens, D, Carpentier, M, Chiusa, S, Lonquety, M, Renault, N, Wong, Y, Cantalloube, H, Chomilier, J, Hochez, J, Pothier, J, Villoutreix, BO, Zagury, JF, Tuffery, P (2005) RPBS: a web resource for structural bioinformatics. Nucleic Acids Res 33: pp. W44-W49 CrossRef
  46. Neron, B, Menager, H, Maufrais, C, Joly, N, Maupetit, J, Letort, S, Carrere, S, Tuffery, P, Letondal, C (2009) Mobyle: a new full web bioinformatics framework. Bioinformatics 25: pp. 3005-3011 CrossRef
  
• 刊物主题：Virology;
• 出版者：BioMed Central
• ISSN：1743-422X

文摘

Background JC polyomavirus (JCPyV) is a widespread human polyomavirus that usually resides latently in its host, but can be reactivated under immune-compromised conditions potentially causing Progressive Multifocal Leukoencephalopathy (PML). Detection of antibodies against the major capsid protein VP1 currently is the main marker for assessment of infection with JCPyV. Methods Based on a peptide microarray, peptide JCPyV_VP2_167-15mer was selected and a peptide ELISA was developed for detection of antibodies directed against this peptide. Epitope mapping and computational modelling was performed to further characterize this peptide. In a cohort of 204 healthy subjects it was investigated whether antibodies against JCPyV_VP2_167-15mer were correlated with VP1 serology or urinary viral load. Results Epitope mapping of peptide JCPyV_VP2_167-15mer showed that the minimal epitope consisted of L173PALTSQEI181 with amino acids P174, L176 and E180 being essential for antibody recognition. Computational analysis was used to predict that this epitope is located at an exposed domain of the VP2 capsid protein, readily accessible for immune recognition upon infection. No correlation could be observed with JCPyV VP1 antibody levels, or urinary viral load. Conclusion This work indicates that specific antibodies against JCPyV_VP2_167-15mer might be considered as a novel serological marker for infection with JCPyV.